Idiopathic pulmonary fibrosis treatment: a dynamic field since 2011

Pirfenidone approved  by EMAPirfenidone approved by the US FDA: evidence on efficacy and safety  observed in previous studies reinforced (ASCEND trial) [33]
Triple therapy outNintedanib approved by the US FDA [33], CHMP of EMA positive opinion:  second antifibrotic drug with positive effects in two phase III trials  (INPULSIS trials) [34]
Anticoagulants outNAC monotherapy out (PANTHER trial) [21]
  • EMA: European Medicines Agency; FDA: Food and Drug Administration; ASCEND: Assessment of Pirfenidone to Confirm Efficacy and Safety in IPF; CHMP: Committee for Medicinal Products for Human Use; NAC: N-acetylcysteine.